Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements

Satoko Oka; Kazuo Ono; Masaharu Nohgawa

doi:10.1002/ccr3.1430

Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements

Clin Case Rep. 2018 Feb 21;6(4):644-650. doi: 10.1002/ccr3.1430. eCollection 2018 Apr.

Authors

Satoko Oka¹, Kazuo Ono², Masaharu Nohgawa¹

Affiliations

¹ Division of Hematology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.
² Division of Pathology Japanese Red Cross Society Wakayama Medical Center Wakayama Japan.

Abstract

Although the clinical significance of hypothyroidism in TAFRO syndrome is unknown, vascular endothelial growth factor (VEGF) levels decreased with improvements in the condition of our refractory TAFRO cases after thyroxine supplement therapy. Our results indicate that elevated VEGF levels are a potential factor in the pathogenesis and anasarca of TAFRO syndrome with hypothyroidism.

Keywords: Hypothyroidism; TAFRO syndrome; idiopathic multicentric Castleman disease; thyroid‐stimulating hormone; vascular endothelial growth factor.

Publication types

Case Reports